Krystal Biotech Inc
Company Overview
Krystal Biotech Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with diseases having high unmet needs. The company's lead product, VYJUVEK, received FDA approval in May 2023 for the treatment of dystrophic epidermolysis bullosa (DEB), a rare genetic condition that causes extremely fragile skin.
The company utilizes its proprietary gene therapy platform, known as STAR-D (Skin TARgeted Delivery platform), to develop treatments for dermatological diseases. Their business model is primarily based on developing and commercializing these therapeutic solutions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $83.84m | $61.41m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $70.28m | $61.72m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $45.25m | $51.93m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Krystal Biotech Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.